【摘要】 目的检测血清中糖类抗原CA125和癌胚抗原(CEA)两种肿瘤标志物的浓度,分析CA125和CEA联合检测在卵巢癌诊断中的临床价值。方法采用全自动化学发光免疫分析法测定23例卵巢癌、37例良性卵巢肿瘤和50例健康体检者外周血清中CA125和CEA的水平,采用t检验进行数据统计分析。结果卵巢癌患者组中CA125和CEA的水平及阳性率分别是(278.43±182.27)U/mL与73.92%、(8.49±8.37)ng/mL与17.4%,明显高于良性卵巢肿瘤组的(23.75±13.59)U/mL与18.92%、(3.43±1.48)ng/mL与0.0%及健康对照组的(12.46±7.65)U/mL与0.0%、(2.21±1.03)ng/mL与0.0%,且差异均有统计学意义(P<0.05)。结论血清CA125与卵巢癌的相关性较理想,CEA与卵巢癌的相关性较差;血清CA125是卵巢癌筛查比较可靠、理想的肿瘤标志物,有较好的诊断价值;而CEA在卵巢癌中也有一定的参考价值,但其阳性率较低。因此CA125和CEA联合检测对卵巢癌的诊断无明显临床价值。更多还原

【Abstract】 Objective To analyse the clinical value of the serum CA125 and carcino embryonic antigen(CEA) combined detection in the patients with ovarian cancer through the detection of 2 kinds of tumor marker concentrations: serum carbohydrate antigen CA125 and carcinoembryonic antigen (CEA). Methods The levels of CA125 and CEA in 23 patients with ovarian cancer, in 37 patients with benign ovarian tumor and in 50 healthy controls were measured by fully automated chemiluminescence immunoassay. Statistical analyses were performed with t test. Results The serum levels and positive rates of CA125 and CEA in patients with ovarian cancer were (278.43±182.27) U/mL and 73.92%, (8.49±8.37) ng/mL and 17.4% respectively, but those in patients with benign ovarian tumor were(23.75±13.59) U/mL and 18.92%, (3.43±1.48) ng/mL and 0.0% respectively, and those with healthy controls were (12.46±7.65) U/mL and 0.0%, (2.21±1.03) ng/mL and 0.0% respectively.The serum levels and positive rates of CA125 and CEA in patients with ovarian cancer were significantly higher than those with benign ovarian tumor and those with healthy controls patients, And the differences were statistically significant (P < 0.05). Conclusion The correlation about serum CA125 with ovarian cancer is ideal, while that with CEA and ovarian cancer is not ideal; so serum CA125 is a more reliable, the ideal tumor marker for screening ovarian cancer, and it has good diagnostic value. CEA has a certain reference value in ovarian cancer , but the positive rate is lower. So CA125 and CEA combined detection in diagnosis of ovarian cancer without significant clinical value.更多还原